ApoB vs LDL-C for Lipid Targets (JAMA 2026)
ApoB vs LDL-C for Lipid Targets (JAMA 2026)
• ApoB-guided therapy > LDL-C for outcomes
• Prevented ~1000 added events / 250,000 patients
Key Findings
• Better CV outcomes
• Cost-effective (~$30K/QALY)
• Requires more intensive therapy
Clinical Insight
* ApoB reflects the number of atherogenic particles; even if each particle carries less cholesterol, a higher number increases the chance of arterial deposition and cardiovascular risk.
* Useful when LDL looks normal but risk remains high.
Limitations / Barriers
• Not routine in lipid panel
• Requires extra test
• Practice change takes time, even with strong evidence.
🎯 Take-Home
ApoB may be better treatment target than LDL-C
Future: more intensive & earlier lipid lowering
Source: JAMA
Published: April 2026,
Medscape (April 24, 2026)
